# A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers

Source: https://onco.cc/trials/nct07233850/  
OnCo record `nct07233850` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SSGJ-706, cAPOX (capecitabine, oxaliplatin) and bevacizumab in pancreatic cancer, run by Shenyang Sunshine Pharmaceutical Co., LTD., not yet recruiting.

## Summary

A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers is a phase 2, interventional study registered as NCT07233850 by Shenyang Sunshine Pharmaceutical Co., LTD., with a registry enrolment figure of 300 participants, started 2025-11 and due to reach its primary completion in 2026-12. Interventions recorded: SSGJ-706+XELOX; SSGJ-706+Bevacizumab+XELOX; SSGJ-706+AG; SSGJ-706+TP. Conditions listed: Gastric/Gastroesophageal Junction Adenocarcinoma; Metastatic Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma (PDAC); Oesophageal Cancer. Primary outcome: Incidence and severity of Adverse Events; Objective response rate (ORR). Pancreatic eligibility wording from the registry: "Locally advanced or metastatic tumors of the digestive system that cannot be curatively resected and cannot be treated with radical chemoradiotherapy, including gastric/gastroesophageal junction adenocarcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, and oesophageal cancer". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07233850
- Phase: 2
- Setting: A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers
- Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD.
- Enrolled: 300

## Sources

- ClinicalTrials.gov NCT07233850: https://clinicaltrials.gov/study/NCT07233850

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [SSGJ-706](https://onco.cc/drugs/ssgj-706/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07233850.json